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 Carcinoembryonic antigen adhesion molecule 1 (CEACAM1) is a human membrane 
glycoprotein belonging to the carcinoembryonic antigen (CEA) family and to the 
immunoglobulin superfamily. It is expressed in apicl membranes of many epithelial cells in 
the gastrointestinal and urogenital tract and also in granulocytes and lymphocytes [1]. Little 
is known about the function of CEACAM1. The role of CEACAM1 as a cell adhesion 
molecule was described first and proved subsequently in numerous in vitro studies. The role 
in signal transduction, its regulation, tumour cell growth regulation, apoptosis, angiogenesis 
and apical membrane organisation have recently beendiscussed in the literature [2, 3, 4]. 
This glycoprotein could influence aggregation of biliary vesicles in supersaturated bile and 
thus speed up cholesterol crystallisation and bile stone formation [5]. There are two isoforms 
of CEACAM1 present in normal human bile, known as CEA AM1-85 and CEACAM1-115, 
according to their apparent molecular weights on SDS–PAGE gel. 
 It was necessary to isolate CEACAM1 from human bile for our studies and 
verification of our hypotheses. CEACAM1 was isolated from human bile by protein 
extraction with perchloric acid, ion-exchange chromatography followed by concanavalin A-
Sepharose affinity chromatography and gel filtrations on Sephadex G200 and Sephacryl 
S200 or Sepharose 4B [6]. Immunoaffinity chromatography was also used for isolation of 
CEACAM1 and other CEA-related antigens from bile [7]. None of the above mentioned 
papers gave any information about the yield and purity of the isolated proteins. 
 To isolate enough amount of pure CEACAM1 from bile for our studies we prepare a 
simple immunoaffinity method based on oriented immobilisation of the monoclonal anti-
CEA antibody on hydrazide-derivatised cellulose. 
 Gangliosides are a family of sialic acid-containing glycosphingolipids located almost 
exclusively in the outer leaflet of the plasma membrane. The carbohydrate moiety of 
gangliosides can mediate cell-cell or cell-matrix interactions that regulate cell growth, cell 
differentiation, and signal transduction in various cell types [8]. Since gangliosides are 
amphiphilic molecules, they have the capability of binding to biological membranes when 
added exogenously. It was previously suggested that this property could be involved in the 
immunosuppressive activity of gangliosides shed from tumour cells. Exogenously added 
brain or tumour gangliosides are capable of inhibiting a variety of immune responses, 
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proliferation, differentiation and secretory responses [9]. The mechanism whereby isolated 
gangliosides modulate the immunoreceptor-mediated signalling is poorly understood. They 
could interact directly with plasma membrane receptors or affect the overall structure of the 
plasma membrane, in particular the properties of glycosphingolipid-enriched membranes 
(GEM), also called lipid rafts. The latter possibility is strengthened by data indicating that 
exogenously added gangliosides could displace GPI-anchored proteins from lipid 
microdomains [10]. Changes in membrane gangliosides could therefore affect the 
immunoreceptor signalling because GEM have been suggested to function as platforms for 
spatial organisation of signal transduction moleculs [11]. 
 In mast cells, the first biochemical event detectable after FcεRI aggregation is 
tyrosine phosphorylation of the FcεRI β and γ subunits by protein tyrosinekinase (PTK) Lyn. 
This process creates new binding sites for Lyn and Syk PTK through Src homology-2 
(SH2)-mediated interactions with phosphotyrosine residues of immunoreceptor tyrosine-
based activation motifs (ITAM). Activation of these newly recruited kinases, in turn, 
facilitates the translocation and phosphorylation of multiple substrates, including the linker 
for activation of T cells (LAT) and phospholipase C (PLC)γ isozymes. These proteins 
interact to form a functional macromolecular signalli g complex at the plasma membrane. 
Activated PLC catalyses the cleavage of the lipid substrate phosphatidylinositol 4,5-
bisphosphate (PIP2) into diacylglycerol, a stimulator of protein kinase C, and inositol 1,4,5-
trisphosphate (IP3), a ligand for the IP3 receptor Ca2+ channel in the endoplasmatic 
reticulum membrane that induces a rise in cytoplasmic Ca2+ levels. An important 
intermediate in this pathway is phosphatidylinositol 3-kinase (PI3K) which catalyses the 
synthesis of phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 3,4-
bisphosphate. All these events result in a formation of large signalling complexes 
responsible for further propagation of the activation signal [12]. 
 In this study, we investigated at which step the gangliosides interfere with FcεRI-
mediated signalling. We used the rat basophilic leuka mia (RBL-2H3) cell line as a model 





 1. To develop an affinity chromatography method to isolate CEACAM1 from human 
bile in sufficiently amount and purity for followed experiment with this glycoprotein. 






3.1. Preparation of immunoaffinity column and isolation f CEACAM1 from bile 
 
 Monoclonal antibody F34-187 [13] was solubilised in 0,1 M acetate buffer, pH 5,5, 
0,1 ml of 0,1 M sodium periodate was added and the antibody was oxidised for 20 min at 
4 °C with shaking. Dialysed antibodies were added to hydrazide cellulose and incubated for 
24 h at 4 °C. Four amino acid contents (alanine, glycine, asparagine and threonine) were 
used for calculation of percentage of the immobilised antibody from the amount of antibody 
used for immobilisation (Biochrom amino acid analyser, Pharmacia, Sweden). 
 The crude protein extract was prepared by perchlori  acid extraction as described by 
Neumaier et al. [7] from 2500 ml of bile obtained via external drainage from the patient with 
benign postcholecystectomic stenosis of the bile duct. The extract was neutralised, dialysed, 
concentrated and lyophilised. The appropriate amount f the crude protein fraction (see 
results) was dissolved in PBS, incubated with immobilised antibody and applied onto the 
column. The non-bound fractions were eluted with 400 ml PBS, the bound antigens were 
then eluted with 6 M guanidine-HCl in PBS and 15 ml fractions were collected. 
 All the fractions obtained from the affinity chromatography were dialysed, 
lyophilised, dissolved in reducing sample buffer and analysed by SDS-PAGE followed by 
immunoblott with polyclonal rabbit anti-CEA antibody (DAKO, Denmark) or lectin staining 
with concanavalin A-HRP (Sigma-Aldrich, USA) according to the method of Laemmli and 
Towbin et al. [14, 15]. The non-specific protein staining with Coomassie brilliant blue G, 
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silver stain kit, amidoblack, sypro orange, sypro red and sypro tangerine (Molecular Probes, 
USA) was performed according to manufacturers’ instructions. Quantification of proteins 
was done by the fluorescamine method according to the standard protocol. 
 
3.2. Methods used for the study of the signalling pathways of FcεRI 
 
3.2.1. Cell activation, immunoprecipitation and immunobloting 
 
 RBL-2H3 (rat basophilic leukaemia) cells were cultured as described [16]. The cells 
were harvested, resuspended at a concentration of 1,5x106 cells/ml in G-medium 
supplemented with or without 50 µM brain gangliosides and incubated for 20 h as 
monolayer. Gangliosides-pretreated and control cells were harvested, resuspended in G-
medium at a concentration 107 cells/ml and sensitised in a suspension with IgE (IGEL b4 1; 
1000 x diluted ascites) or biotinylated OX7 mAb (3 µg/ml). After 30 min at 37 °C in 5 % 
CO2 in air, the cells were washed in BSS supplemented with 0,1 % BSA and activated at 
37 °C by exposure to TNP-BSA (1 µg/ml) or streptavidin (10 µg/ml). In cells activated via 
FcεRI dimers, the sensitisation step was omitted and the cells were directly activated by 5.14 
mAb anti FcεRI α subunit. β-glucuronidase released (degranulation) into supernatant was 
measured as described [17, 18]. The cell pellets were lysed in a ice-cold lysis buffer 
containing 50 mM Tris-HCl (pH 7,4), 150 mM NaCl, 2 mM EDTA, 10 mM 
β-glycerophosphate, 1 mM Na3VO4, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin and 
supplemented with 1 % NP-40 and 1 % n-dodecyl β-D-maltoside (LAT, Syk and PLC γ IP) 
or 0,2 % Triton X-100 (FcεRI IP). Post nuclear supernatants were IP with corresponding 
antibodies prebound to UltraLink-immobilised Protein A (Pierce), size fractionated by SDS-
PAGE and immunoblotted with the corresponding antibod es as described [19]. Aliquots of 
post nuclear supernatants (corresponding to 0,25x106 cells) were examinated for tyrosine 
phosphorylation in whole cell lysate proteins. 
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3.2.2. Sucrose density gradient fractionation 
 
 Labelling of mAb with 125I (ICN biomedicals, USA) by chloramine-T method and 
isolation of GEM by sucrose density gradient ultracentrifugation has been described [20]. 
 
3.2.3. PIP3 and IP3 determination 
 
 PIP3 was detected by a modification of a previously described procedure [21] 
adapted for the microcentrifuge tubes. Briefly, cells at a concentration 107/ml in BSS/BSA 
were incubated with 200 µCi/ml [32P]orthophosphate (Amersham Pharmacia Biotech, UK) 
for 1 h at 37 °C before stimulation with TNP-BSA. The reaction was stopped by centrifuging 
and resuspending the pellet in 500 µl of ice-cold methanol : chloroform (2:1, v/v) follwed 
350 µl of ice-cold chloroform and 350 µl of 1,2 M HCl. The tubes were vortexed, 
centrifuged, and the organic phase (400 µl) was reextracted with 400 µl of methanol : 0,6 M 
HCl (1:1, v/v). After centrifugation the organic phase (300 µl) was dried, resuspended and 
applied to thin-layer chromatography Silica gel-60 plates (Merck, Germany) precoated with 
potassium oxalate (1,2 % in 40 % methanol). Chromatgr phy was performed in a mixture 
of chloroform : acetone : methanol : acetic acid : water (80:30:26:24:14, all v/v). Radioactive 
phospholipids were detected by autoradiography and quantified by densitometry. 
Phosphoinositides (Sigma and Matreya, USA) of known composition were used as a 
standard and detected by exposing the plates to iodine vapours. 
 IP3 was determined as described by [22]. Briefly, 6x106 RBL-2H3 cell pretreated or 
not with gangliosides were sensitised with IgE (anti TNP) and stimulated with TNP-BSA in 
500 µl BSS/BSA. At various time intervals the reactions were terminated by adding 100 µl 
of ice-cold trichloracetic acid (100 %). IP3 was extracted from the samples and quantified 
using a commercially available assay kit (PerkinElmer, USA). 
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3.2.4. Calcium mobilisation 
 
 Changes in the concentration of free intracellular Ca2+ ([Ca2+] i) in ganglioside-
pretreated or control cells were determined using Fluoro-3-AM or Fura Red-AM probe 
(Molecular Probes, USA) as previously described [20, 23, 24, 25].  
 
3.2.5. F-actin assay 
 
 Total amount of polymeric actin was determined as previously described [26]. 
Briefly, to 200 µl of the cell suspension (106 cells) in BSS/BSA was added 300 µl of PBS 
containing 50 µg lysophosphatidylcholine (Sigma), 6 % formaldehyde and 0,125 µg of 
FITC-labelled phalloidin (Sigma). After incubation for 10 min at 37 °C the cells were 
centrifuged, resuspended in PBS and analysed by flow cytofluorometry using FACSCalibur 
(Becton Dickinson, USA). 
 
3.2.6. Immune complex PI3K and PLCγ assays 
 
 PI3K activity was measured as previously described with minor modifications [27]. 
FcεRI-activated or control RBL-2H3 cells (2x106) were solubilised in 500 µl lysis buffer 
(20 mM Tris-HCl (pH 8,0), 137 mM NaCl, 2 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 
10 µg/ml aprotinin and leupeptin) supplemented with 1 % Triton X-100. PI3K in post 
nuclear supernatants was immunoprecipitated with anti-PI3K p85 subunit Ab and the 
immunocomplexes were collected on UltraLink immobilised protein A (10 µl). The beads 
were washed twice with lysis buffer supplemented with 0,1 % Triton X-100, twice with 
kinase assay buffer (20 mM HEPES (pH 7,4), 20 mM MgCl2 and 0,25 mM EGTA), and then 
suspended in 25 µl kinase buffer with or without 100 nM wortmannin. After 10 min at 
25 °C, PI3K assay was initiated by an addition of 25 µl of kinase buffer containing 10 µg of 
sonicated phosphatidylinositol (Sigma-Aldrich) and 37 kBq [γ-32P]ATP (Amersham 
Pharmacia Biotech; final concentration 10 µM) and the reaction mixture was incubated for 
30 min at 25 °C. During this period, the formation f phosphatidylinositol phosphate was 
linear (data not shown). The reaction was terminated by adding 250 µl 
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methanol : chloroform (2:1, v/v), chloroform (175 µl), and 1,2 M HCl (175 µl). The organic 
phase was extracted again with 200 µl methanol : 0,6 M HCl (1:1, v/v) and lyophilised. 
Lipids were resuspended in 15 µl of chloroform : methanol (1:1, v/v), spotted on TLC Silica 
gel-60 plate (Merck), precoated with potassium oxalate and resolved in 
chloroform : methanol : 4 M ammonium hydroxide (9:7:2, v/v/v) for 1 h. 32P-labelled 
materials were visualised by autoradiography and quantified by Fuji Bio-Imaging Analyzer 
Bas 5000 (Tokyo, Japan). 
 PLCγ assay was performed essentially as described [28]. FcεRI-activated or control 
RBL-2H3 cells were solubilised in a lysis buffer (20 mM HEPES (pH 7,5), 150 mM NaCl, 
5 mM β-glycerophosphate, 0,2 mM Na3VO4, 1 mM EGTA, 1 mM PMSF, 1 µg/ml aprotinin, 
and 1 µg/ml leupeptin) supplemented with 1 % Triton X-100. PLCγ1 or PLCγ2 in post 
nuclear supernatants were immunoprecipitated with the corresponding antibodies and the 
immunocomplexes were bounded on UltraLink immobilised protein A. The beads (15 µl) 
were washed and then suspended in 25 µl reaction buffer. After addition of 10 µl substrate 
solution containing 25 mM sodium phosphate (pH 6,8), 50 mM KCl, 2,5 % Triton X-100, 
6 µg of PIP2 and 1,1 kBq of P[3H]IP2 (PerkinElmer), the beads were incubated for 30 min at 
35°C. TCA precipitates were removed by centrifugation and the supernatants collected for 
quantification of the released [3H]IP3 by liquid scintillation counting. Immunocomplexes 
bound to the pelleted beads were solubilised in SDS-PAGE sample buffer and analysed by 
immunoblotting for the presence of PLCγ. 
 
3.2.7. Statistical analysis 
 
 Data are expressed as means ± SD. Statistical analysis was performed by two-tail 




4.1. Isolation of CEACAM1 from bile 
 
 The affinity column 2,0 (i.d.) × 4,5 cm, bed volume 14 ml, was used for preparative 
chromatography and obtained data were recalculated per 1 ml of the gel volume. We 
immobilised 0,75 mg of mAb F34-187 anti-CEA per ml of hydrazide cellulose. The actual 
amount of the immobilised antibody was determined using analysis of amino acids and this 
method was compared with the UV spectrophotometry (280 nm). Using amino acid analysis, 
four amino acids that are completely released after 24 h hydrolysis (alanine, glycine, 
threonine and asparagine) were used for calculation. From obtained values it was calculated 
that approximately 0,3 mg of antibody per ml of hydrazide cellulose were immobilised from 
originally used 0,75 mg per ml. The higher amount (0,6 mg/ml) was obtained when the UV 
spectrophotometry was used. 
 About 1,27 g of lyophilised crude protein fraction e riched with CEACAM1 was 
obtained from 2500 ml of human bile by extraction with perchloric acid. Samples of 2,9 mg 
and 5,6 mg of the crude protein fraction per ml of hydrazide cellulose were loaded onto the 
column. The recovery of the eluted protein was 135 ± 49 and 361 µg/ml bed volume, 
respectively, as determined by spectrofluorometry (for details see Table 1). Higher load of 
the protein extract did not lead to the increase of recovery of isolated protein. 
 The aliquot of protein sample loaded onto the affinity column, the aliquots of the 
non-bound fractions washed out from the column and the fractions eluted with 6 M 
guanidine hydrochloride were analysed by SDS-PAGE and immunoblott with the polyclonal 
rabbit anti-CEA antibody (Dako, Denmark). A single 85 kDa band of non-bound 
glycoprotein could be detected in the original sample and in the first washing fractions. No 
immunopositivity was found in last washing fraction Wx, but a strong signal appeared again 
in the fractions E1-E3 eluted with guanidine-HCl, see Figure 1. 
 In order to detect other protein bands possibly presented in the sample of 
immunopurified CEACAM1, the following methods of non-specific protein staining were 
tested: silver staining, Coomassie brilliant blue, Sypro orange, Sypro red, Sypro tangerine 
and amidoblack and India ink. With these methods, we were able to detect multiple protein 
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bands in the crude protein but no bands could be visualised in the affinity-purified fractions 
E1-E3. The only band that could be silver stained in the affinity purified fractions when 
higher amounts of protein were loaded onto the gel was that of albumin. The 
immunopurified CAECAM1-85, which appeared to be the most abundant biliary isoform of 
CEACAM1 present in the fraction according to immunochemical staining, did not stain at 
all. The only method which could detect the 85 kDa band was staining with concanavalin A-
HRP on the blot followed by the ECL kit (Amersham Pharmacia Biotech), see Figure 2. 
 
Table 1: Experimental data obtained from affinity chromatography 
Column No. 1 2 
Column i. d. × column length (cm) 2,0 × 4,5 2,0 × 4,5 
Bed volume (ml) 14 14 
Concentration of mAb loaded (mg/ml bed) 0,75 0,75 
Concentration of the immobilised mAb based on amino acid analysis 
(mg/ml bed) 0,3 0,3 
Concentration of the immobilised mAb based on UV spectrometry 
(mg/ml bed) 0,6 0,6 
Crude extract load (mg/ml bed) 2,9 5,6 
Recovered CEACAM1(µg/ml bed) 135 ± 49 361 











Figure 1: Immunostaining (with anti-CEA polyclonal antibody) of fractions from affinity column after SDS-
PAGE. S - aliquot of protein sample isolated by extraction with TCA. N - non-bound protein also containing 
small amount of unbound immunopositive protein. Non-b und protein was washed out in several fractions (see
W1). No immunopositive band was observed in the last fraction after extensive washing with 400 ml of PBS 
(Wx). Change of the washing buffer for 6 M guanidine hydrochloride led to the elution of immunopositive 
protein in fractions E1-E3. 
 
 
Figure 2: Lectin staining of crude protein after extraction with perchloric acid (lane 1) and of the 
immunopurified CEACAM1 (lane 2). The membrane was blocked with 50 mM Tris-HCl containing 0,15 M 
NaCl and 0,01 % Tween-20 for 1 h, incubated with concanavalin A-peroxidase (2 mg/ml) in a similar buffer 
containing 0,5 M NaCl for 1 h, washed 3 × 10 min with the blocking buffer, and detected with ECL kit. 6,25 µg 
of the total protein was loaded onto each lane. 
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4.2. Exogenous administration of gangliosides inhibits FcεRI-mediated mast cell 
degranulation by decreasing the activity of phospholi ase Cγ 
 
4.2.1. Exogenously added gangliosides selectively inhibit the FcεRI mediated secretory 
response 
 
 A preincubation of RBL-2H3 cells with highly purified human brain gangliosides 
inhibited the β-glucuronidase release induced by antigen-mediated aggregation of IgE-FcεRI 
complexes (Figure 3A). Pilot experiments indicated that the maximum inhibition was 
observed after incubation of the cells for 20 h with gangliosides at a concentration 50 µM in 
G-medium. Under these conditions, gangliosides did not exhibit any cytotoxic effect as 
determined by trypan blue dye exclusion test. A similar inhibitory effect was observed when 
the FcεRI was aggregated by anti-FcεRI mAb 5.14 (Figure 3B). The inhibitory effect was 
specific for FcεRI-mediated activation, because it was absent in Thy-1 glycoprotein 
activated cells, which responded even more than control cells (Figure 3C). The maximal 
inhibitory effect was seen at an antigen concentration hat gave a maximum secretory 
response in control cells (1 µg/ml; Figure 3D). 
 Gangliosides present in the human brain differ in their sialic acid and carbohydrate 
chain moieties. To determine whether the inhibitory effect is confined to specific 
gangliosides, we compared the effect of monosialoganglioside GM1, asialo-GM1, 
disialoganglioside GD1a and trisialoganglioside GT1b on FcεRI-mediated secretory 
response. Preincubation of the RBL-2H3 cells with GM1 significantly inhibited the secretory 
response although the inhibition was weaker compared with brain gangliosides (Figure 3E). 
Interestingly, asialo-GM1 inhibited the secretory response to a similar extent as GM1, 
suggesting that sialic acid had no significant role in the inhibitory effect of GM1. 
Pretreatment with GT1b and GD1a, the dominant brain g gliosides, resulted in a decrease 
of the secretory response, which was comparable to the inhibition observed after 
pretreatment with isolated brain gangliosides. Because of these results, isolated brain 




Figure 3: Exogenously administered gangliosides selectively inhibit FcεRI-mediated secretion. A–D, RBL-
2H3 cells were incubated for 20 h with 50 µM isolated brain gangliosides in G-medium () or with G-medium 
alone (). After incubation, the cells were sensitised for 30 min with TNP-specific IgE (A and D), biotinylated 
anti-Thy-1.1 mAb OX7 (C), or not sensitised (B). The cells were activated by aggregation of the IgE-FcεRI 
complexes by TNP-BSA (A; 1 µg/ml), dimerisation of FcεRI by 5.14 mAb (B; 1 µg/ml) or aggregation of Thy-
1-biotinylated OX7 complexes by streptavidin (Str; 10 µg/ml; C). The amount of β-glucuronidase released into 
the supernatant was determined at various time intervals. In D, IgE-sensitised cells were stimulated with 
various concentrations of TNP-BSA, and β-glucuronidase was determined after 30 min. In E, the cells were 
pretreated for 20 h with G-medium supplemented with 50 µM GT1b (), GD1a (), GM1 (), asialo-GM1 
() or in G medium alone (), and activated as in A. Means ± SD of 4 (A–D) or 2 (E) independent 
experiments performed in duplicates or triplicates are presented. 
 
 Gangliosides-pretreated cells, compared with control cells, exhibited a decreased 
adhesion to the substratum, with a more rounded morphology and with less developed 
processes (Figure 4, A and B). Similar changes in cell morphology were observed in cells 
pretreated with GT1b, GD1a, GM1 and asialo-GM1 (not shown). These changes were 
associated with the decreased amount of F-actin observed in nonactivated gangliosides-
pretreated cells (inhibition 17 ± 7%; mean ± SD; n = 5; p < 0,01). After antigen-mediated 
activation, the amount of F-actin was significantly higher in both gangliosides-pretreated and 
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control cells. In the former, however, the levels of F-actin remained lower at all time 






Figure 4: Morphology and F-actin of ganglioside-pretreated cells. RBL-2H3 cells were incubated with 
isolated brain gangliosides in G-medium (A) or in G-medium alone (B). Phase contrast images were taken after 
20 h. Bar = 10 µm. C, The amount of F-actin in ganglioside-pretreated () or control cells () was determined 
by flow cytofluorometry in IgE-sensitised cells activated for various time intervals by TNP-BSA (1 µg/ml). 
Means ± SD were calculated from five independent experiments. 
 
4.2.2. Gangliosides do not prevent the association of aggregated FcεRI with GEM 
 
 When aggregated, the FcεRI rapidly associate with GEM [29]. Because it has been 
shown that brain gangliosides interfere with the int grity of GEM [10], we further analysed 
the solubility of FcεRI in cells exposed to isolated gangliosides. Our data indicate that the 
majority of nonaggregated FcεRI from both control and gangliosides-pretreated cells 
solubilised in 0,06 % Triton X-100 was located in the high-density fractions of sucrose 
gradient (>35 % sucrose) and after aggregation most of the IgE-FcεRI complexes from both 
control and treated cells were found in the low-density fractions (15-35 % sucrose). 
However, a significant amount of FcεRI was still found in the high-density fractions (>55% 
sucrose); it probably represents the cytoskeleton bund aggregated FcεRI, which differs 
from the GEM-associated FcεRI. It could be concluded that gangliosides had no significant 
effect on this association. Thus, the observed inhib tory effect of gangliosides on FcεRI-
mediated secretion in RBL-2H3 cells does not seem to be a direct consequence of reduced 




4.2.3. Decreased tyrosine phosphorylation and enzymatic activity of PLCγ in 
gangliosides pretreated cells 
 
 In an attempt to determine whether exogenous gangliosides inhibit early FcεRI-
mediated signalling events we further analysed tyrosine phosphorylation of FcεRI, Syk, LAT 
and PLCγ. Tyrosine phosphorylation of FcεRI β and γ subunits, Syk PTK and LAT was not 
inhibited by pretreatment with gangliosides. In fact, tyrosine phosphorylation of LAT was 
increased in antigen-activated cells in all 3 performed experiments (+46,6 ± 11,6 %). 
Although PLCγ1 and PLCγ2 from both gangliosides-pretreated and control cells bound to 
LAT comparably (Figure 5B), their tyrosine phosphorylation was significantly reduced 
(Figure 5A). These data suggested that exogenous gangliosides could affect activity of PLCγ. 
 
 
Figure 5: Tyrosine phosphorylation and interaction of PLCγ. RBL-2H3 cells were incubated with isolated 
brain gangliosides in G-medium (+Ga) or in G-medium alone (-Ga), sensitised with IgE and activated (+) or 
not (-) with TNP-BSA (1 µg/ml). A, Tyrosine phosphorylation of PLCγ1 and 2 was detected by 
phosphotyrosine immunoblotting (IB) with PY20 mAb (Transduction Laboratories, USA) after IP. The 
quantity of proteins in IP was assessed by immunoblotting with appropriate antibodies on stripped membranes. 
The relative amount of tyrosine phosphorylated proteins of ganglioside pretreated and stimulated cells are 
given in percent of stimulated controls. B, Association of LAT with PLCγ1 and PLCγ2 was determined after IP 
of LAT followed by immunoblotting with PLCγ1; PLCγ2 and LAT antibodies. Similar results were obtained in 
three independent experiments. Arrows indicate position of the corresponding proteins. 
 
 Full activation of PLCγ requires its membrane recruitment by an interaction with 
LAT and PI3K lipid products [30]. Major function of PLCγ there is to hydrolyse PIP2 to IP3 
and diacylglycerol, which induce the release of Ca2+ from intracellular stores and the 
 19 
activation of protein kinase C (PI3K), respectively. The primary in vivo substrate of PI3K is 
PIP2, which is converted to PIP3. In additional experiments we measured the levels of PIP3 
in the course of the activation of gangliosides pretreated as well as control cells. In 
gangliosides pretreated cells the baseline level of PIP3 was decreased and these levels were 
also significantly lower in antigen-activated cells, compared with cells cultured in media 
without gangliosides (time 0). It should be noted that exogenously added gangliosides also 
reduced the baseline PIP2 levels (inhibition 21 ± 8%; mean ± SD; n = 4; p < 0.05). The 
differences between control and gangliosides pretreated cells after antigen triggering were 
not significant (Figure 6A and B). 
 The observed decrease in PIP3 levels could be the result of a decreased activity of 
PI3K, an increased activity of the corresponding phosphatases and/or a decreased availability 
of PI3K substrate. In additional experiments, we threfore evaluated the PI3K activity by 
immunocomplex kinase assay. PI3K was IP from control o  gangliosides pretreated cells 
activated for various time intervals with antigen. Data presented in Figure 6C indicate that 
control cells incubated for 20 h in the absence of gangliosides exhibited a relatively rapid 
increase in PI3K activity after exposure to antigen (2,5-fold increase in 15 s) which declined 
after 5 min. Pretreatment with gangliosides did not i hibit PI3K activity but resulted instead 
in its increase, especially at early time intervals after the exposure to antigen. A significant 
increase of PI3K activity was also observed after pr treatment of the cells with GD1a and 
GT1b gangliosides, the major components of brain gangliosides (Figure 6C). As expected, 
pretreatment of PI3K immunocomplexes with 100 nM wortmannin completely inhibited the 
formation of 32P labelled PIP. These data indicate that the observed decrease in PIP3 levels 




Figure 6: PIP3 levels and activity of PI3K in gangliosides pretreated and antigen-stimulated cells. A and B, 
RBL-2H3 cells were incubated in the presence (+Ga) or absence (-Ga) of isolated brain gangliosides and then 
sensitised with IgE. PIP3 levels were measured in [32P]orthophosphate-labelled cells before (0 min) and 
following stimulation with TNP-BSA (1 µg/ml). The TLC separation pattern was determined using 
phosphoinositide standards. A representative TLC is shown (A). Quantitative measurement of PIP3 level, 
corrected for the total signal from phosphatidylinosit l monophosphates PIP1, PIP2 and PIP3, in controls () 
or ganglioside pretreated cells (▓) was determined by densitometry of films (B). Data are presented as means ± 
SD, calculated from four independent experiments, and normalised to nonstimulated control cells. C, PI3K 
enzymatic activity was measured in cells preincubated with G-medium alone (-Ga) or G-medium supplemented 
with 50 µM brain gangliosides (+Ga), GD1a or GT1b. The cells were stimulated with antigen for various time 
intervals and PI3K activity was determined as described in 3.2.3. Samples labelled 5w and 1w were from cells 
stimulated with antigen for 5 min and 1 min and the immunocomplexes were exposed for 10 min to 100 nM 
wortmannin before PI3K assay. Migration of PIP is indicated by arrow. Representative results are shown on top 
panels. Quantitative measurements of PIP were normalised to unstimulated control cells and to the amount of 
PI3K detected by immunoblotting of whole cell lysates. Means of fold increase ± SD were calculated from 
three to five independent experiments. 
 
 Decreased tyrosine phosphorylation of PLCγ1 and PLCγ2 in gangliosides pretreated 
cells suggested their reduced enzymatic activity. To prove that the activity of PLCγ is indeed 
reduced, we measured the PLCγ activity in an immunocomplex assay. In control cells 
preincubated in G-medium alone, the activities of PLCγ1 and PLCγ2 were increased ~6-fold 
and 8-fold, respectively, after 1 min exposure to antigen, and then declined (Figure 7A and 
B). Pretreatment with gangliosides inhibited the activity of both enzymes at all time intervals 
analysed. The observed inhibition was not due to decreased levels of the enzymes as could 
be inferred from the results of immunoblotting analyses of PLCγ1 and PLCγ2 IP from 
control and gangliosides pretreated cells (not shown). 
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 Our findings that gangliosides inhibit the activity of PLCγ were supported by 
measurements of IP3 levels in control and gangliosides pretreated cells after stimulation with 
antigen (Figure 7C). In control cells, antigen stimulation induced a rapid augmentation of 
IP3 concentrations, with a peak at 15 s, followed by a slow return to baseline levels. In 
gangliosides-pretreated cells, the baseline level of IP3 was comparable to that in control cells 
at time 0 min, but was significantly reduced after stimulation with antigen (Figure 7C). The 
reduced IP3 levels in gangliosides-pretreated and activated cells were reflected in a 
decreased calcium response after activation in media supplemented with Ca2+ (Figure 7D), 
as well as in the absence of Ca2+ (Figure 7E). Exogenously added gangliosides had no effect 
on Ca2+ response induced by calcium ionophore A23187 (Figure 7F), suggesting that the 
signal transduction pathways involving PLCγ, rather than Ca2+ channels, are modulated by 
gangliosides. 
Activation (s)
Activation (s)  
Figure 7: Exogenously administered gangliosides inhibit the enzymatic activity of PLCγ, and Ca2+ 
mobilisation in antigen-activated cells. RBL-2H3 cells were incubated in the presence () or absence () of 
isolated brain gangliosides and then sensitised with IgE. A and B) Enzymatic activities of PLCγ1 and PLCγ2 
were measured by immune complex PLC assay as describ d in 3.2.3. Cells were collected before or at various 
time intervals after stimulation with TNP-BSA. Means ± SD were calculated from two to three experiments 
performed in duplicates. C) IP3 levels were measured before and after stimulation with TNP-BSA. Samples 
were collected at the indicated times. Means ± SD of three independent experiments performed in duplicates 
are presented. D–F) Calcium response in Fluo-3- and Fura-Red-loaded cells. The cells were pretreated (dash-
dot line) or not (solid line) with gangliosides, sen itised with IgE (D and E) or not (F), and stimulated in the 
presence (D and F) or absence (E) of extracellular calcium with TNP-BSA (1 µg/ml; D and E, arrow, antigen), 
or calcium ionophore A23187 (1 µg/ml; F, arrow A23). Fluorescence intensity was determined by flow 
cytofluorometry. 
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4.2.4. Formation of signalling assemblies in gangliosides-pretreated cells 
 
 Previously a simple method for determination of thesubcellular translocations of 
signal transduction molecules was described [31]. The method is based on a gentle release of 
free cytoplasmic components after permeabilisation of the cells with the cholesterol 
sequestering reagent saponin, followed by complete solubilisation of all membrane 
components, including lipid rafts, by the detergent NP40. Using a modified version of this 
method we first compared the subcellular distribution of PLCγ2 and its phosphorylated form, 
in both control and gangliosides-pretreated cells. 
 The data presented in Figure 8A indicate that FcεRI aggregation in saponin 
permeabilised cells is followed by a rapid and transie t increase in the amount of tyrosine 
phosphorylated PLCγ2 (arrow) and associated proteins. The observed change was in part due 
to an increased amount of insoluble PLCγ2 remaining in permeabilised cells, as 
demonstrated by immunoblotting with anti-PLCγ2 antibody. Pretreatment with gangliosides 
of saponin permeabilised cells reduced the amount of tyr sine phosphorylated PLCγ2 and 
coimmunoprecipitated proteins. This effect was in part related to a decrease in the amount of 
insoluble PLCγ2 and was most profound 5 min after antigen triggerin . Because of the 
observed changes in cellular morphology and the decreased amount of F-actin in 
gangliosides-pretreated cells, we also analysed the tyrosine phosphorylation of ezrin, which 
functions as an intermediate between the actin cytoskeleton and integral plasma membrane 
proteins [32]. Although the amount of ezrin bound to permeabilised control cells (-Ga) did 
not show any significant change in the course of cell activation, its tyrosine phosphorylation 
was dramatically increased 30 s after activation, ad then declined. Pretreatment with 
gangliosides decreased the amount of ezrin in saponin permeabilised cells. Interestingly, the 
background level of tyrosine phosphorylated ezrin (0 min) was higher in gangliosides 
pretreated cells than in control cells, and FcεRI aggregation resulted in a decreased tyrosine 
phosphorylation of ezrin in gangliosides-pretreated cells (Figure 8B). Finally, we 
investigated the distribution of Akt, which is recruited to the plasma membrane in activated 
cells by virtue of its interaction with PIP3 and phosphatidylinositol 3,4-bisphosphate [33]. In 
control cells (-Ga) the amount of tyrosine phosphorylated Akt in saponin permeabilised cells 
increased during FcεRI activation (Figure 8C). However, this increase was due not only to 
an augmentation of Akt tyrosine phosphorylation, but was mainly attributable to an 
increased association of Akt with insoluble material in saponin permeabilised cells, as 
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indicated by anti-Akt immunoblotting. In gangliosides-pretreated cells, both Akt tyrosine 
phosphorylation and its association with insoluble material were reduced. 
 
 
Figure 8: Decreased formation of PLCγ2-, Ezrin- and Akt-containing signalling assemblies in gangliosides-
pretreated cells. RBL-2H3 cells were incubated with isolated brain gangliosides in G-medium (+Ga) or in G-
medium alone (-Ga), sensitised with IgE, and activated with TNP-BSA (1 µg/ml). After the indicated time 
intervals, the cells were spun down and resuspended in permeabilisation buffer containing 0,1 % saponin, 
followed by centrifugation and extraction of the “empty” cells with NP40. The insoluble material (nuclei and 
cytoskeleton) was removed by centrifugation and the supernatant immunoprecipitated with anti-PLCγ2-coated 
protein A beads (A) or anti-ezrin-coated protein G beads (B) before SDS-PAGE and immunoblotting with anti-
phosphotyrosine antibody (PY20). Alternatively, the supernatant was directly analysed by SDS-PAGE and 
immunoblotting with anti-phospho-Akt (pAkt) antibody (C). After stripping, the membranes were tested for the 
presence of PLCγ2, ezrin, and Akt with the corresponding antibodies. Arrows in A, B, and C indicate, 




 Carcinoembryonic cell adhesion molecule 1 (CEACAM1) is a human membrane 
glycoprotein. At the first part of this thesis we dscribe method for isolation of CEACAM1 
glycoprotein from bile and characterise its efficiency and recovery. We used affinity 
chromatography with immobilised monoclonal anti-CEA F34-187 antibodies. This method 
based on the oxidation of the immunoglobulin carbohydrate component located on the Fc 
fragment of antibody by periodate and oriented bounding to hydrazide-derivated matrix. 
Crude protein fraction obtained from bile by TCA precipitation was applied onto the affinity 
column and CEACAM1 was eluted with 6 M guanidine-HCl. A single immunopositive 
85 kDa band of CEACAM1 was detected on the western blot with anti-CEA antibody. 
Probably due to the high glycosylation of CEACAM1 any common method of protein 
staining was not applicable except staining with lectin. 
 The second part describes an effect of exogenous gangliosides on signalling of mast 
cells. Gangliosides released from tumour cells, as well as administered exogenously, 
suppress the immune responses by largely unknown mechanisms. We show here that a 
pretreatment of rat basophilic leukaemia cells (RBL-2H3) with isolated brain gangliosides 
inhibited the release of preformed secretory mediators (β-glucuronidase) from cells activated 
via FcεRI but not via Thy-1 glycoprotein. Exogenously administered gangliosides also 
affected the cell-substrate adhesion and the levels of polymeric filamentous actin (F-actin) in 
antigen-activated cells. Although the production of phosphoinositides was also decreased, 
enzymatic activity of phosphatidylinositol 3-kinase (PI3K) was not inhibited. Gangliosides 
had no or only marginal effect on the association of aggregated FcεRI with 
glycosphingolipid-enriched membranes (GEM) and on tyrosine phosphorylation of FcεRI. 
Though pretreatment with gangliosides did not inhibit the association of LAT with 
phospholipase C (PLCγ1 and PLCγ2), but tyrosine phosphorylation of these enzymes, as 
well as their enzymatic activities and association with detergent-insoluble signalling 
assemblies were reduced. This resulted in a decreased production of inositol 1,4,5-
trisphosphate (IP3) and an inhibition of Ca2+ mobilisation. The combined data support the 
concept that exogenously administered gangliosides int rfere with those properties of GEM 
that are important for the formation of plasma membrane-associated signalling assemblies 




BSA   bovine serum albumin 
BSS  20 mM HEPES (pH 7,4), 135 mM NaCl, 5 mM KCl, 1,8 mM CaCl2, 
1 mM MgCl2 a 5,6 mM glucose 
[Ca2+] i   concentration of free intracellular Ca
2+ 
CEA   carcinoembryonic antigen 
CEACAM1 carcinoembryonic antigen cell adhesion molecu  1 
EDTA  ethylendiamintetraacetic acid 
F-actin  polymeric filamentous actin 
FcεRI  high affinity IgE receptor 
GEM  glycosphingolipid-enriched membrane domain 
G-medium 1:1 RPMI 1640 a MEM (minimum essential medium) with 1 mM 
natrium pyruvat and 3 mM L-glutamine, penicillin (100 U/ml), 
streptomycin (100 µg/ml), D-glucose (2,5 mg/ml) and 1 % (v/v) fetal 
calf serum. 
GM1   monosialogangliosid, II3NeuAcGgOse4Cer 
GD1a  disialogangliosid, IV3NeuAc II3NeuAcGgOse4Cer 
GT1b  trisialogagliosid, IV3NeuAc II3 (NeuAc)2GgOse4Cer 
GPI   glycosyl-phosphatidylinositol 
HEPES  N-2-hydroxyethylpiperazin-N´-ethansulfonic acid 
HRP   horseradish peroxidase 
IP   immunoprecipitation 
IP3   inositol 1,4,5-triphosphate 
LAT   linker for activation of T cells 
mAb   monoclonal antibody 
NP40   Nonidet-P40 
PBS  phosphate buffered saline: 80 mM Na2HPO4, 20 mM NaH2PO4, 
100 mM NaCl; pH 7,4 
PI3K    phosphatidylinositol 3-kinase 
PIP2   phosphatidylinositol 4,5-bisphosphate 
PLCγ1, PLCγ2 phospholipase C, isoforms γ1 a γ2 
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PMSF   phenylmethylsulfonylfluorid (inhibitor of serine proteases) 
PTK   protein tyrosinkinase 
PY20   anti-phosphotyrosine antibody 
SDS-PAGE  sodium dodecyl sulphate- polyacrylamide gel electrophoresis 
TLC   thin-layer chromatography 
TNP   2,4,6-trinitrophenyle 
Tris-HCl  2-amino-2-(hydroxymethyl)-1,3-propandiol hydrochloride 
Triton X-100  t-octylphenoxypolyethoxyethanol, non-i ic detergent 
Tween 20  polyoxyethylene sorbitan monolaurate, non-ionic detergent 
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